MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma

• Published in: Cancer letters 2015-01, Vol.356 (2), p.809-818
• Main Authors: Ni, Fang, Zhao, Hua, Cui, Huaqin, Wu, Zhengsheng, Chen, Li, Hu, Zhongqian, Guo, Chuang, Liu, Yakun, Chen, Zhuo, Wang, Xinyi, Chen, Danlei, Wei, Haiming, Wang, Siying
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - metabolism; Carcinoma, Hepatocellular - secondary; Cell Adhesion; Cell growth; Cell Movement; Cell Proliferation; CYLD; Deubiquitinating Enzyme CYLD; Gene expression; Hematology, Oncology and Palliative Medicine; Hepatocellular carcinoma; Humans; Immunoenzyme Techniques; Kinases; Leukemia; Liver cancer; Liver Neoplasms - genetics; Liver Neoplasms - metabolism; Liver Neoplasms - pathology; Metastasis; Mice; Mice, Nude; MicroRNAs; MicroRNAs - genetics; miR-362-5p; Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; RNA, Small Interfering - genetics; Studies; Tumor Cells, Cultured; Tumor Suppressor Proteins - antagonists & inhibitors; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; Xenograft Model Antitumor Assays
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2014.10.041

Highlights • MiR-362-5p is frequently up-regulated in hepatocellular carcinoma (HCC) and associated with HCC progression. • Inhibition of miR-362-5p significantly decreases HCC cell proliferation, clonogenicity, migration, and invasion in vitro. • Inhibition of miR-362-5p dramatically suppresses HCC tumor growth and metastasis in vivo. • MiR-362-5p targets CYLD through its 3′-UTR in HCC cells. • MiR-362-5p acts through CYLD to activate the NF-κB signaling pathway, which contributes to HCC progression.